Corrigendum.

Abstract

Developmental Medicine & Child NeurologyVolume 59, Issue 12 p. 1315-1315 CorrigendumFree Access Corrigendum This article corrects the following: Leukodystrophies and genetic leukoencephalopathies in childhood: a national epidemiological study Lesley A Stellitano, Anne Marie Winstone, Marjo S Knaap, Christopher M Verity, Volume 58Issue 7Developmental Medicine & Child Neurology pages: 680-689 First Published online: February 11, 2016 First published: 14 November 2017 https://doi.org/10.1111/dmcn.13573AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Leukodystrophies and genetic leukoencephalopathies in childhood: a national epidemiological study In the article by Stellitano et al.,1 the calculations of the lifetime risk of leukodystrophies in children in the United Kingdom were erroneous. To find the number of live births during the period May 1997 to November 2014 inclusive, the authors used the Office of National Statistics (ONS) data set for England and Wales, which was 11 252 927, rather than the data set for the United Kingdom, which was 13 076 173.2 The paper's abstract on page 680 reports that for the leukodystrophies there was an estimated lifetime risk of 31 per million live births; this should be corrected to 26.7 per million. The relevant results on page 681 (in the results section, paragraph 2) should have read as follows: ‘The estimated lifetime risk per million UK live births for the whole leukodystrophy group was 26.7. For the nine most common leukodystrophies it was: metachromatic leukodystrophy 5.8, X-linked adrenoleukodystrophy (including asymptomatic X-ALD) 5.7, Krabbe disease 4.2, Aicardi-Goutières disease 1.9, Alexander disease 1.5, Canavan disease 1.4, vanishing white matter disease 1.3, Pelizaeus-Merzbacher disease 1.2, and megalencephalic leukoencephalopathy with subcortical cysts 0.8.’ On page 685, the result for Krabbe disease (4.9/million) should be corrected to 4.2 per million, and the lifetime adrenoleukodystrophy risk (6.6/million) should be corrected to 5.7 per million. The authors apologize for these errors. References 1Stellitano LA, Winstone AM, van der Knaap MS, Verity CM. Leukodystrophies and genetic leukoencephalopathies in childhood: a national epidemiological study. Dev Med Child Neurol 2016; 58: 680– 9. 2 Office for National Statistics. Vital Statistics: Population and Health Reference Tables. 28 November 2016. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/vitalstatisticspopulationandhealthreferencetables (accessed 18 April 2017). Volume59, Issue12December 2017Pages 1315-1315 ReferencesRelatedInformation